Cargando…

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer

PURPOSE: Identification of effective biomarkers for the benefit of endocrine treatment and understanding the molecular pathways that contribute to the development of resistance are of crucial importance to the management of luminal breast cancer. The amino acid transporter SLC1A5 has emerging import...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alfarsi, Lutfi H., El Ansari, Rokaya, Craze, Madeleine L., Mohammed, Omar J., Masisi, Brendah K., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357718/ https://www.ncbi.nlm.nih.gov/pubmed/34282517 http://dx.doi.org/10.1007/s10549-021-06298-1

Ejemplares similares

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer
por: El Ansari, Rokaya, et al.
Publicado: (2020)

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer
por: Masisi, Brendah K., et al.
Publicado: (2021)

Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer
por: Ansari, Rokaya El, et al.
Publicado: (2019)

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development
por: Aljohani, Abrar I., et al.
Publicado: (2022)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

Liver Disease and Risk of Hepatocellular Carcinoma in Children With Mutations in TALDO1
por: Grammatikopoulos, Tassos, et al.
Publicado: (2021)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer
por: Morotti, Matteo, et al.
Publicado: (2020)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Connexin 43 is an independent predictor of patient outcome in breast cancer patients
por: Chasampalioti, Maria, et al.
Publicado: (2018)

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer
por: Elsharawy, Khloud A., et al.
Publicado: (2020)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2020)

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
por: Ahmad, Dena A. J., et al.
Publicado: (2016)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
por: Joseph, Chitra, et al.
Publicado: (2020)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer
por: Kariri, Yousif, et al.
Publicado: (2022)

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
por: Muftah, Abir A., et al.
Publicado: (2017)

Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray
por: Parks, R. M., et al.
Publicado: (2020)

Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients
por: Mirza, Sameer, et al.
Publicado: (2013)

The Effect of Estrogen on Intracellular Ca(2+) and Na(+) Regulation in Heart Failure
por: Firth, Jahn M., et al.
Publicado: (2020)

Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
por: Zhao, Xiangshan, et al.
Publicado: (2012)

Two isoforms of TALDO1 generated by alternative translational initiation show differential nucleocytoplasmic distribution to regulate the global metabolic network
por: Moriyama, Tetsuji, et al.
Publicado: (2016)

The intra-tumoural stroma in patients with breast cancer increases with age
por: Vangangelt, Kiki M. H., et al.
Publicado: (2019)

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics
por: Groenendijk, Floris H., et al.
Publicado: (2013)

Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-α activity on breast metabolic signaling
por: Arnone, Alana A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0m3n75bkkbds8fajorrhufe6so